Antitumor Activity and Treatment-Related Toxicity Associated With Nivolumab Plus Ipilimumab in Advanced Malignancies: A Systematic Review and Meta-Analysis-Reference-Cited by-同舟云学术

Antitumor Activity and Treatment-Related Toxicity Associated With Nivolumab Plus Ipilimumab in Advanced Malignancies: A Systematic Review and Meta-Analysis

Published:2019-11-04 Issue: Volume:10 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Xu Hang,Tan Ping,Ai Jianzhong,Zhang Shiyu,Zheng Xiaonan,Liao Xinyang,Yang Lu,Wei Qiang

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference40 articles.

1. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study;Antonia;Lancet Oncol.,2016

2. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial;Antonia;Lancet Oncol.,2016

3. A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952);Bazhenova;J. Clin. Oncol.,2019

4. CTLA-4 and PD-1 Pathways: similarities, differences, and implications of their inhibition;Buchbinder;Am. J. Clin. Oncol.,2016

5. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study;Calabro;Lancet Respir. Med.,2018

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Occult checkpoint inhibitor myocarditis during adjuvant nivolumab plus ipilimumab: a smoldering but severe toxicity;Immunotherapy;2024-09-11

2. Cytokine release syndrome associated with immune checkpoint inhibitors: a pharmacovigilance study based on spontaneous reports in FAERS;Expert Opinion on Drug Safety;2024-07-29

4. Cytokine release syndrome complicated with severe rashes induced by nivolumab plus ipilimumab therapy in a patient with non‐small cell lung cancer: A case report;Thoracic Cancer;2023-06-28

5. First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors;Journal of Hematology & Oncology;2023-05-08